Canada: Rapid Response 2016

Submit A Letter of Intent

Sign in to our online system or register for a new account to submit a letter of intent.

Apply Now

*The deadline for submitting applications to the Canada: Rapid Response 2016 program has now passed.*

The prevalence of neurodegenerative diseases of aging is high and growing rapidly.  The Rapid Response program was created to catalyze and jumpstart the development of safe and effective treatments for these diseases. The program provides short-term grants as seed funding for novel, high-risk, high-reward translational research projects that advance the development of therapeutics for neurodegenerative diseases of aging. Proposed projects may relate to any disease; however, the basis for selection will be on the potential impact of the project on neurodegenerative diseases of aging.

NEW this year:

  • Rapid Response 2016 will run three times within the 2016 calendar year, and each round of applications will be tied to a specific disease group (outlined below)
  • Each lab can only submit 1 LOI per round of applications
  • ALS projects should submit to ALS 2016, which will accept both Rapid Response and Transformational Research applications

Funding and Eligibility

Projects can request up to $150,000 over up to 18 months.

Applicants must be researchers or postdoctoral fellows from institutions that are CRA qualified donees in Canada.

New for Rapid Response 2016: The Institute will have three application rounds, each focused on one of two disease groups:

Group 1 (Rounds 1 and 3):         AD-related diseases (AD, FTD, MCI and prodromes)

Group 2 (Round 2):         PD-related diseases (PD, PSP, DLB, MSA and prodromes)

* Projects focused on ALS should be submitted to the ALS-focused program scheduled to launch in Spring 2016.

**Applicants should apply to the category best suited to their project. Projects that have impact on multiple neurodegenerative diseases of aging should apply to the most appropriate program.

Proposed projects must fall into one of two categories:

Development of a therapeutic

  • A pharmacological approach, e.g., drugs (including small molecules, biologics, cell therapies and vaccines, and including drug repositioning and repurposing), animal models, imaging techniques, reagents, biomarkers, diagnostics, medical devices, surgical interventions, or magnetic or electrical brain stimulation; but not complementary approaches. Therapeutics can be for symptomatic relief, disease modification, or prevention.

Development of tools that help accelerate development of therapeutic

  • An item that accelerates the development of therapeutics, e.g.,  drugs (including small molecules, biologics, cell therapies and vaccines), medical devices or surgical interventions.

Important Dates

Round 3: AD-related diseases (AD, FTD, MCI and prodromes)

Information Session: August 10th, 2016 1:00 pm EDT
LOI deadline:  September 12th, 2016 2:00 pm EDT


Application Process

Within each round of applications, there will be two stages to the application process:

  1. Letters of Intent (LOI)
  2. Proposals

An application for the Rapid Response program requires a Letter of Intent. Applicants with high potential projects will be invited to submit a Proposal; instructions will be forwarded along with the invitation.

Request for Applications (RFA)

Letter of Intent

Program Details


Program Information Sessions

The Weston Brain Institute held an online Program Information Session for Round 3 of this funding opportunity on Wednesday, August 10th.


The Institute welcomes inquiries about the Rapid Response 2016 Program or any of our other funding programs to neuro@weston.ca or 416-935-4056.